title: An ionic liquid-in-water microemulsion as a potential carrier for topical delivery of poorly water soluble drug: Development, ex-vivo and in-vivo evaluation.
abstract: In this paper, we report an ionic liquid-in-water (IL/w) microemulsion (ME) formulation which is able to solubilize etodolac (ETO), a poorly water soluble drug for topical delivery using BMIMPF6 (1-butyl-3-methylimidazolium hexafluorophosphate) as IL, Tween 80 as surfactant and ethanol as co-surfactant. The prepared ME was characterized for physicochemical parameters, subjected to ex-vivo permeation studies as well as in-vivo pharmacodynamic evaluation. The ex-vivo drug permeation studies through rat skin was performed using Franz-diffusion cell and the IL/w based ME showed maximum mean cumulative percent permeation of 99.030±0.921% in comparison to oil-in-water (o/w) ME (61.548±1.875%) and oily solution (48.830±2.488%) of ETO. In-vivo anti-arthritic and anti-inflammatory activities of the prepared formulations were evaluated using different rodent models and the results revealed that ETO loaded IL/w based ME was found to be more effective in controlling inflammation than oily solution, o/w ME and marketed formulation of ETO. Histopathological studies also demonstrated that IL/w based ME caused no anatomical and pathological changes in the skin.
authors.affiliation: University Institute of Pharmaceutical Sciences, UGC-Centre for Advanced Studies, Panjab University, Chandigarh 160014, India. Electronic address: shishugoindi@yahoo.co.in.
authors.forename: Shishu
authors.initials: S
authors.lastname: Goindi
authors.affiliation: University Institute of Pharmaceutical Sciences, UGC-Centre for Advanced Studies, Panjab University, Chandigarh 160014, India.
authors.forename: Ramanpreet
authors.initials: R
authors.lastname: Kaur
authors.affiliation: University Institute of Pharmaceutical Sciences, UGC-Centre for Advanced Studies, Panjab University, Chandigarh 160014, India.
authors.forename: Randeep
authors.initials: R
authors.lastname: Kaur
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D004355:Drug Stability; D004655:Emulsions / Q000008:administration & dosage / Q000737:chemistry; D017308:Etodolac / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D007093:Imidazoles / Q000008:administration & dosage / Q000737:chemistry*; D066298:In Vitro Techniques; D052578:Ionic Liquids / Q000008:administration & dosage* / Q000737:chemistry; D008297:Male; D010539:Permeability; D051381:Rats; D012212:Rheology; D012869:Skin Absorption; D012995:Solubility; D014867:Water / Q000737:chemistry*
chemical_list: C412621:1-butyl-3-methylimidazolium hexafluorophosphate; D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D004655:Emulsions; D007093:Imidazoles; D052578:Ionic Liquids; D014867:Water; D017308:Etodolac
keywords: Anti-arthritic; Anti-inflammatory; Etodolac; Ionic liquid; Microemulsion; Topical delivery